Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed
- PMID: 11679973
- DOI: 10.1053/jhep.2001.28509
Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed
Abstract
We used a new real-time polymerase chain reaction (PCR)-based assay that is sensitive, has a wide dynamic linear range, and is highly reproducible to quantify hepatitis B virus (HBV) DNA in the serum of infected individuals undergoing potent antiviral therapy. In addition, we made frequent measurements of viral load after initiation of treatment and maintained follow-up to about 12 weeks. To analyze the data we used a new model of HBV decay, which takes into account that existing drug treatments do not completely block de novo infection and the possibility of noncytolytic loss of infected cells. On initiation of therapy, there was a mean delay of 1.6 days followed by a biphasic or muliphasic decay of plasma HBV DNA. The slope of the first phase varied considerably, with one individual having rapid decay, corresponding to a virion half-life of 1 hour, but others showing half-lives of up to 92 hours. Individuals either had a slow second-phase decline (t((1/2)) = 7.2 +/- 1.2 days) or a flat second phase. Some individuals exhibited a complex "staircase pattern" of decay, with further phases of viral DNA decline and phases with little change in viral load.
Similar articles
-
Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.J Infect Dis. 2000 Feb;181(2):713-6. doi: 10.1086/315238. J Infect Dis. 2000. PMID: 10669360
-
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.Hepatology. 2000 Nov;32(5):1078-88. doi: 10.1053/jhep.2000.19619. Hepatology. 2000. PMID: 11050059
-
Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.Liver Int. 2004 Apr;24(2):98-104. doi: 10.1111/j.1478-3231.2004.0889.x. Liver Int. 2004. PMID: 15078472 Clinical Trial.
-
Hepatitis B virus kinetics and mathematical modeling.Semin Liver Dis. 2004;24 Suppl 1:11-6. doi: 10.1055/s-2004-828673. Semin Liver Dis. 2004. PMID: 15192796 Review.
-
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.Am J Gastroenterol. 2002 Jul;97(7):1618-28. doi: 10.1111/j.1572-0241.2002.05819.x. Am J Gastroenterol. 2002. PMID: 12135009 Review.
Cited by
-
Hepadnavirus Genome Replication and Persistence.Cold Spring Harb Perspect Med. 2015 Jul 1;5(7):a021386. doi: 10.1101/cshperspect.a021386. Cold Spring Harb Perspect Med. 2015. PMID: 26134841 Free PMC article. Review.
-
Development of mathematical models for the analysis of hepatitis delta virus viral dynamics.PLoS One. 2010 Sep 16;5(9):e12512. doi: 10.1371/journal.pone.0012512. PLoS One. 2010. PMID: 20862328 Free PMC article.
-
Innate immune surveillance of the circulation: A review on the removal of circulating virions from the bloodstream.PLoS Pathog. 2022 May 5;18(5):e1010474. doi: 10.1371/journal.ppat.1010474. eCollection 2022 May. PLoS Pathog. 2022. PMID: 35511797 Free PMC article. Review.
-
HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage.World J Gastroenterol. 2004 Jan;10(1):82-5. doi: 10.3748/wjg.v10.i1.82. World J Gastroenterol. 2004. PMID: 14695774 Free PMC article.
-
Effect of the initial dose of foot-and-mouth disease virus on the early viral dynamics within pigs.J R Soc Interface. 2009 Oct 6;6(39):835-47. doi: 10.1098/rsif.2008.0434. Epub 2008 Nov 19. J R Soc Interface. 2009. PMID: 19019816 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical